STOK: Stoke Therapeutics, Inc.
About
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Current Value
$11.491 Year Return
Current Value
$11.491 Year Return
Key Details
Market Cap
$614.95M
P/E Ratio
-5.53
1Y Stock Return
197.69%
1Y Revenue Growth
81.04%
Dividend Yield
0.00%
Price to Book
2.6
Strategies that include STOK
Stock's related to STOK
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DNUT | 39.75% | $1.84B | -15.32% | 1.30% |
| HCSG | 38.63% | $832.59M | +14.29% | 0.00% |
| ENTA | 37.71% | $199.60M | -5.52% | 0.00% |
| MESO | 36.40% | $1.23B | +347.11% | 0.00% |
| KOD | 35.71% | $296.80M | +150.67% | 0.00% |
| PGEN | 35.23% | $228.91M | -28.00% | 0.00% |
| SMTC | 34.60% | $3.55B | +213.68% | 0.00% |
| VKTX | 34.37% | $5.74B | +353.83% | 0.00% |
| PLRX | 33.76% | $778.32M | -9.55% | 0.00% |
| KRYS | 32.78% | $5.12B | +75.65% | 0.00% |
| SNBR | 32.67% | $263.31M | +5.09% | 0.00% |
| MKC | 32.66% | $20.21B | +15.19% | 2.23% |
| ALEC | 32.24% | $377.04M | -19.46% | 0.00% |
| BLNK | 32.19% | $156.82M | -57.53% | 0.00% |
| CLFD | 31.85% | $398.66M | +4.48% | 0.00% |
| SANA | 31.36% | $526.91M | -41.15% | 0.00% |
| SNDL | 31.19% | $525.69M | +33.78% | 0.00% |
| RLAY | 30.93% | $803.44M | -39.70% | 0.00% |
| GBIO | 30.83% | $92.84M | +20.87% | 0.00% |
| ALT | 29.73% | $531.30M | +194.09% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CATX | -0.01% | $458.24M | +162.59% | 0.00% |
| WRAP | -0.02% | $62.86M | -49.45% | 0.00% |
| IMMP | -0.02% | $293.82M | +8.31% | 0.00% |
| TLK | 0.03% | $16.88B | -27.18% | 6.58% |
| VST | -0.11% | $52.69B | +349.00% | 0.56% |
| TXO | 0.11% | $737.26M | -1.80% | 13.22% |
| SBLK | 0.13% | $2.38B | +2.30% | 10.64% |
| SRRK | -0.15% | $2.61B | +134.91% | 0.00% |
| NVDA | 0.15% | $3.61T | +194.35% | 0.07% |
| TKC | -0.19% | $5.80B | +35.51% | 1.30% |
| CDLX | 0.20% | $178.39M | -54.00% | 0.00% |
| CMG | 0.20% | $80.02B | +33.62% | 0.00% |
| EOG | 0.20% | $76.03B | +10.19% | 2.70% |
| KHC | 0.21% | $36.98B | -10.45% | 5.23% |
| X | -0.21% | $8.76B | +13.32% | 0.51% |
| GOGL | 0.22% | $2.39B | +35.11% | 8.40% |
| EDU | 0.22% | $9.06B | -22.20% | 0.00% |
| CLMT | 0.26% | $1.79B | +35.14% | 0.00% |
| CCEC | -0.30% | $1.02B | +28.03% | 3.26% |
| CRIS | 0.37% | $32.09M | -55.52% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TEM | -11.88% | $8.50B | 0.00% | 0.00% |
| CYD | -10.45% | $364.46M | -2.94% | 4.26% |
| TCTM | -9.82% | $8.10M | -42.99% | 0.00% |
| XOS | -9.76% | $30.51M | -57.24% | 0.00% |
| NERV | -9.24% | $14.69M | -58.00% | 0.00% |
| CYCN | -9.04% | $4.77M | -16.19% | 0.00% |
| HUSA | -7.90% | $16.69M | -11.56% | 0.00% |
| CBOE | -7.26% | $21.46B | +15.84% | 1.11% |
| IP | -6.56% | $20.09B | +78.02% | 3.20% |
| GDS | -5.89% | $3.72B | +79.40% | 0.00% |
| NNE | -5.88% | $833.66M | +531.50% | 0.00% |
| WM | -5.66% | $87.92B | +27.58% | 1.34% |
| HES | -5.56% | $45.06B | +1.32% | 1.24% |
| SEG | -5.46% | $319.72M | +12.41% | 0.00% |
| SOLV | -5.14% | $11.58B | -16.19% | 0.00% |
| NEXA | -4.92% | $1.02B | +30.44% | 0.00% |
| BP | -4.91% | $77.24B | -18.61% | 6.32% |
| SCWX | -4.83% | $743.12M | +40.27% | 0.00% |
| BVN | -4.54% | $3.16B | +37.49% | 0.00% |
| QDEL | -4.18% | $2.59B | -44.25% | 0.00% |
ETF's related to STOK
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| RSPA | 47.29% | $273.87M | 0% |
| XBI | 46.59% | $6.58B | 0.35% |
| GNOM | 41.91% | $70.59M | 0.5% |
| PTH | 41.47% | $143.31M | 0.6% |
| IBB | 41.39% | $6.66B | 0.45% |
| PBE | 38.94% | $258.53M | 0.58% |
| IWC | 37.95% | $933.99M | 0.6% |
| XPH | 37.66% | $157.87M | 0.35% |
| ARKG | 36.96% | $1.13B | 0.75% |
| IWO | 36.76% | $12.56B | 0.24% |
| FBT | 35.89% | $1.11B | 0.56% |
| VTWO | 35.85% | $12.38B | 0.1% |
| ISCG | 35.77% | $640.00M | 0.06% |
| IWM | 35.70% | $75.73B | 0.19% |
| FXH | 35.69% | $1.15B | 0.62% |
| QQA | 35.09% | $135.01M | 0% |
| NUSC | 34.97% | $1.27B | 0.31% |
| ESML | 34.91% | $1.90B | 0.17% |
| BBH | 34.84% | $397.87M | 0.35% |
| SLYG | 34.46% | $3.69B | 0.15% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TPMN | -0.16% | $40.60M | 0.65% |
| CCOR | -0.19% | $109.04M | 1.18% |
| KRBN | -0.20% | $242.47M | 0.85% |
| JBBB | -0.35% | $1.26B | 0.49% |
| BSCO | 0.37% | $2.35B | 0.1% |
| DUSB | -0.38% | $797.63M | 0.15% |
| GCC | -0.52% | $133.23M | 0.55% |
| DBB | 0.76% | $126.37M | 0.77% |
| DBA | 0.83% | $755.88M | 0.93% |
| FLRN | -0.86% | $2.33B | 0.15% |
| GBIL | -1.26% | $5.60B | 0.12% |
| CLOI | 1.44% | $715.40M | 0.4% |
| IBTE | 1.59% | $1.70B | 0.07% |
| FLTR | 1.70% | $1.79B | 0.14% |
| USCI | -1.73% | $185.47M | 1.07% |
| FLRT | 1.74% | $401.26M | 0.6% |
| CSHI | -1.84% | $482.85M | 0.38% |
| HDRO | -1.96% | $164.26M | 0.3% |
| MINT | -1.98% | $11.62B | 0.35% |
| BILZ | 2.06% | $563.02M | 0.14% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -27.96% | $388.04M | 1.43% |
| VIXY | -19.93% | $195.31M | 0.85% |
| CORN | -13.25% | $61.12M | 0.2% |
| DBE | -12.72% | $50.13M | 0.77% |
| DBO | -11.37% | $217.57M | 0.77% |
| UUP | -11.16% | $309.25M | 0.77% |
| COMT | -11.05% | $829.06M | 0.48% |
| GSG | -11.01% | $914.42M | 0.75% |
| KCCA | -10.86% | $220.51M | 0.87% |
| PDBC | -10.80% | $4.40B | 0.59% |
| EQLS | -10.33% | $76.08M | 1% |
| CTA | -10.12% | $350.27M | 0.78% |
| USDU | -10.09% | $201.97M | 0.5% |
| KMLM | -9.93% | $353.87M | 0.9% |
| SOYB | -7.33% | $27.32M | 0.22% |
| IBDP | -6.57% | $2.11B | 0.1% |
| DBC | -6.56% | $1.39B | 0.87% |
| WEAT | -5.81% | $120.27M | 0.28% |
| FTGC | -4.26% | $2.17B | 1.02% |
| BCI | -4.12% | $1.20B | 0.26% |
News
Yahoo
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Yahoo
The average of price targets set by Wall Street analysts indicates a potential upside of 66.8% in Stoke Therapeutics (STOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Yahoo
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders will have a reason to smile today, with the analysts making...
Yahoo
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 9.62% and 41.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
BEDFORD, Mass., November 05, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for the third quarter of 2024 and provided business updates including those related to zorevunersen, the Company’s proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome
Yahoo
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.